Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

pembrolizumab (8 cycles)

Trade Name:
Keytruda
Company:
Status:
Completed (Results Pending)
Agent Chaperone(s):
Treatment Protocol:
Pembrolizumab is a PD-1 Inhibitor. The dose regimen is as follows: Paclitaxel (q1w × 12 weeks) and pembrolizumab (q3w ×24 weeks).Option only for participants enrolled before Feburary 9th 2018, paclitaxel (q1w x 12 weeks) + pembrolizumab (q3w x 12 weeks); followed by AC + pembrolizumab (q3w x 12 weeks). Cycles 13,14,15 and 16 are given as AC + pembrolizumab combination every 3 weeks.
Date Entered I-SPY:
July 21, 2017
Date Left I-SPY:
No. Participants in Arm:
Graduating Subtypes:
Agent Description:

Pembrolizumab (Keytruda) is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes.The "pembro8" arm of the study is evaluating 8 cycles of pembrolizumab treatment, as opposed to 4 cycles in the previously evaluated arm.

Notes:
Final pCR Probabilities:
Primary Manuscript:
 
abstractpdfdoi link